View Item 

Show simple item record

Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project

dc.contributor.authorMajumdar, Suvankar
dc.contributor.authorBean, Christopher J.
dc.contributor.authorDe Staercke, Christine
dc.contributor.authorBost, James
dc.contributor.authorNickel, Robert
dc.contributor.authorCoates, Thomas
dc.contributor.authorCampbell, Andrew
dc.contributor.authorThompson, Alexis
dc.date.accessioned2020-07-02T20:33:12Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-07-02T20:33:12Z
dc.date.issued2020-06
dc.identifier.citationMajumdar, Suvankar; Bean, Christopher J.; De Staercke, Christine; Bost, James; Nickel, Robert; Coates, Thomas; Campbell, Andrew; Thompson, Alexis (2020). "Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project." Transfusion Medicine 30(3): 226-230.
dc.identifier.issn0958-7578
dc.identifier.issn1365-3148
dc.identifier.urihttps://hdl.handle.net/2027.42/155921
dc.publisherBlackwell Publishing Ltd
dc.publisherWiley Periodicals, Inc.
dc.subject.otherhemoglobinopathy
dc.subject.othersickle
dc.subject.otherparvovirus B19
dc.titleParvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155921/1/tme12671_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155921/2/tme12671.pdf
dc.identifier.doi10.1111/tme.12671
dc.identifier.sourceTransfusion Medicine
dc.identifier.citedreferenceJuhl D, Gorg S, Hennig H. Persistence of parvovirus B19 (B19V) DNA and humoral immune response in B19V‐infected blood donors. Vox Sang. 2014; 107 ( 3 ): 226 ‐ 232.
dc.identifier.citedreferenceZimmerman SA, Davis JS, Schultz WH, Ware RE. Subclinical parvovirus B19 infection in children with sickle cell anemia. J Pediatr Hematol Oncol. 2003; 25 ( 5 ): 387 ‐ 389.
dc.identifier.citedreferenceMakhlouf MM, Elwakil SG, Ibrahim NS. Molecular and serological assessment of parvovirus B‐19 infection in Egyptian children with sickle cell disease. J Microbiol Immunol Infect. 2017; 50 ( 5 ): 565 ‐ 569. https://doi.org/10.1016/j.jmii.2015.10.016.
dc.identifier.citedreferenceSlavov SN, Kashima S, Pinto AC, Covas DT. Human parvovirus B19: general considerations and impact on patients with sickle‐cell disease and thalassemia and on blood transfusions. FEMS Immunol Med Microbiol. 2011; 62 ( 3 ): 247 ‐ 262.
dc.identifier.citedreferenceSlavov SN, Haddad SK, Silva‐Pinto AC, et al. Molecular and phylogenetic analyses of human parvovirus B19 isolated from Brazilian patients with sickle cell disease and beta‐thalassemia major and healthy blood donors. J Med Virol. 2012; 84 ( 10 ): 1652 ‐ 1665.
dc.identifier.citedreferenceCohen BJ, Beard S, Knowles WA, et al. Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Transfusion. 1997; 37 ( 9 ): 947 ‐ 952.
dc.identifier.citedreferenceHeegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev. 2002; 15 ( 3 ): 485 ‐ 505.
dc.identifier.citedreferenceLindblom A, Heyman M, Gustafsson I, et al. Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy. Clin Infect Dis. 2008; 46 ( 4 ): 528 ‐ 536.
dc.identifier.citedreferenceCrabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013; 56 ( 7 ): 968 ‐ 977.
dc.identifier.citedreferenceLiefeldt L, Buhl M, Schweickert B, et al. Eradication of parvovirus B19 infection after renal transplantation requires reduction of immunosuppression and high‐dose immunoglobulin therapy. Nephrol Dial Transplant. 2002; 17 ( 10 ): 1840 ‐ 1842.
dc.identifier.citedreferenceNickel RS, Osunkwo I, Garrett A, et al. Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy. Br J Haematol. 2015; 169 ( 4 ): 574 ‐ 583.
dc.identifier.citedreferenceKern C KT. RealStar® Parvovirus B19 PCR Kit 1.0 from Altona Diagnostics. Hamburg, Germany; 2017. https://www.altona-diagnostics.com/files/public/Content%20Homepage/-%2002%20RealStar/MAN%20-%20CE%20-%20EN/RealStar%20Parvovirus%20B19%20PCR%20Kit%201.0_WEB_CE_EN-S03.pdf.
dc.identifier.citedreferenceJames C, Karen C, Funke G, Jorgensen JH, Landry ML, Warnock DW. Manual of Clinical Microbiology. 10th ed. Washington, DC: ASM Press; 2015.
dc.identifier.citedreferenceMolenaar‐de Backer MW, Russcher A, Kroes AC, Koppelman MH, Lanfermeijer M, Zaaijer HL. Detection of parvovirus B19 DNA in blood: viruses or DNA remnants? J Clin Virol. 2016; 84: 19 ‐ 23.
dc.identifier.citedreferenceKleinman SH, Glynn SA, Lee TH, et al. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion. 2007; 47 ( 10 ): 1756 ‐ 1764.
dc.identifier.citedreferenceBallou WR, Reed JL, Noble W, Young NS, Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis. 2003; 187 ( 4 ): 675 ‐ 678.
dc.identifier.citedreferenceBuchanan G, Yawn B, Afenyi‐Annan A, Ballas S, Hassell K, James A, Jordan L, Lanzkron S, Lottenberg R, Savage W, Tanabe P, Ware R, Murad MH. Evidence‐Based Management of Sickle Cell Disease: Expert Panel Report. Washington, DC: National Institute of Health (NIH)/National Heart Lung Blood Institute (NHLBI). 2014.
dc.identifier.citedreferenceOpoka RO, Ndugwa CM, Latham TS, et al. Novel use of Hydroxyurea in an African region with malaria (NOHARM): a trial for children with sickle cell anemia. Blood. 2017; 130 ( 24 ): 2585 ‐ 2593.
dc.identifier.citedreferenceTshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell Anemia in sub‐Saharan Africa. N Engl J Med. 2019; 380 ( 2 ): 121 ‐ 131.
dc.identifier.citedreferenceCassinotti P, Bas S, Siegl G, Vischer TL. Association between human parvovirus B19 infection and arthritis. Ann Rheum Dis. 1995; 54 ( 6 ): 498 ‐ 500.
dc.identifier.citedreferenceReid DM, Reid TM, Brown T, Rennie JA, Eastmond CJ. Human parvovirus‐associated arthritis: a clinical and laboratory description. Lancet. 1985; 1 ( 8426 ): 422 ‐ 425.
dc.identifier.citedreferenceOgunsile FJ, Currie KL, Rodeghier M, Kassim A, DeBaun MR, Sharma D. History of parvovirus B19 infection is associated with silent cerebral infarcts. Pediatr Blood Cancer. 2018; 65 ( 1 ). https://doi.org/10.1002/pbc.26767.
dc.identifier.citedreferenceMurray KO, Garcia MN, Yan C, Gorchakov R. Persistence of detectable immunoglobulin M antibodies up to 8 years after infection with West Nile virus. Am J Trop Med Hyg. 2013; 89 ( 5 ): 996 ‐ 1000.
dc.identifier.citedreferenceHankins JS, Penkert RR, Lavoie P, Tang L, Sun Y, Hurwitz JL. Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era. Exp Biol Med (Maywood ). 2016; 241 ( 7 ): 749 ‐ 754.
dc.identifier.citedreferenceSmith‐Whitley K, Zhao H, Hodinka RL, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood. 2004; 103 ( 2 ): 422 ‐ 427.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
tme12671_am.pdf
Size:
263.9KB
Format:
PDF
View/Open
Name:
tme12671.pdf
Size:
519.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.